What is the role of the bone marrow microenvironment in AML?

Nirupama Mulherkar; David T Scadden

doi:10.1016/j.beha.2021.101328

What is the role of the bone marrow microenvironment in AML?

Best Pract Res Clin Haematol. 2021 Dec;34(4):101328. doi: 10.1016/j.beha.2021.101328. Epub 2021 Oct 23.

Authors

Nirupama Mulherkar¹, David T Scadden²

Affiliations

¹ Medical Writing Consultant, NM-INK, LLC, USA. Electronic address: nirupama@nmink.com.
² Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA; Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA. Electronic address: dscadden@mgh.harvard.edu.

PMID: 34865700
DOI: 10.1016/j.beha.2021.101328

Abstract

Acute myeloid leukemia (AML) continues to be associated with relapse and resistance to chemotherapy. The bone marrow microenvironment in AML has been shown to regulate responsiveness to chemotherapy and to support disease progression. This review summarizes some recent experimental insights into the crucial role of the bone marrow microenvironment in AML and persistence after chemotherapy.

Keywords: AML; Acute myeloid leukemia; Bone marrow microenvironment; Chemotherapy persistence; Hematopoietic stem cells; Leukemic stem cells; Metabolism; Niche; mTORC1.

Publication types

Review

MeSH terms

Bone Marrow*
Disease Progression
Humans
Leukemia, Myeloid, Acute* / drug therapy
Tumor Microenvironment